About
CTG Pharma's solution enables chimeric antigen receptor (CAR) T therapy for HER2-positive solid tumors while mitigating toxicity and on-target off-tumor reactions. CTG Pharma's solutions include a library of 65,000 promoters that enable safer CAR T for the treatment of solid tumors, applicable to any CAR and suitable for a variety of tumor micro-environment conditions. CTG Pharma aims to create a broadly applicable platform to enhance the safety and efficacy of a variety of human CAR T therapies requiring regulation of CAR expression. The platform is composed of a rationally designed library of 65,000 different switches, for minimal immune response in healthy tissues and maximum expression of the CAR specifically in the tumor surroundings. It is a highly sensitive system that integrates unique signals from the solid tumor microenvironment for the regulation of CAR expression. The company's first line of products is HER2-positive cancers.